318 related articles for article (PubMed ID: 3053900)
1. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
[TBL] [Abstract][Full Text] [Related]
2. Human C5a and C5a des Arg exhibit chemotactic activity for fibroblasts.
Senior RM; Griffin GL; Perez HD; Webster RO
J Immunol; 1988 Nov; 141(10):3570-4. PubMed ID: 3183381
[TBL] [Abstract][Full Text] [Related]
3. Specific inhibitor of complement (C5)-derived chemotactic activity in systemic lupus erythematosus related antigenically to the Bb fragment of human factor B.
Perez HD; Hooper C; Volanakis J; Ueda A
J Immunol; 1987 Jul; 139(2):484-9. PubMed ID: 3648093
[TBL] [Abstract][Full Text] [Related]
4. Role of chemotactic factor inactivator in modulating alveolar macrophage-derived neutrophil chemotactic activity.
Robbins RA; Justice JM; Rasmussen JK; Russ WD; Thomas KR; Rennard SI
J Lab Clin Med; 1987 Feb; 109(2):164-70. PubMed ID: 3805869
[TBL] [Abstract][Full Text] [Related]
5. Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells.
Charo IF; Yuen C; Perez HD; Goldstein IM
J Immunol; 1986 May; 136(9):3412-9. PubMed ID: 3514759
[TBL] [Abstract][Full Text] [Related]
6. Antigenic identification of chemotactic factor inactivator in normal human serum and bronchoalveolar lavage fluid.
Robbins RA; Rasmussen JK; Clayton ME; Gossman GL; Kendall TJ; Rennard SI
J Lab Clin Med; 1987 Sep; 110(3):292-9. PubMed ID: 3611952
[TBL] [Abstract][Full Text] [Related]
7. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.
Perez HD; Lipton M; Goldstein IM
J Clin Invest; 1978 Jul; 62(1):29-38. PubMed ID: 659635
[TBL] [Abstract][Full Text] [Related]
8. Characterization of endotoxin-induced C5-derived chemotactic activity in aqueous humor.
Rosenbaum JT; Wong K; Perez HD; Raymond W; Howes EL
Invest Ophthalmol Vis Sci; 1984 Oct; 25(10):1184-91. PubMed ID: 6384121
[TBL] [Abstract][Full Text] [Related]
9. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg.
Marder SR; Chenoweth DE; Goldstein IM; Perez HD
J Immunol; 1985 May; 134(5):3325-31. PubMed ID: 3884709
[TBL] [Abstract][Full Text] [Related]
10. Generation of a neutrophil chemotactic agent by spermatozoa: role of complement and regulation by seminal plasma factors.
Clark RA; Klebanoff SJ
J Immunol; 1976 Oct; 117(4):1378-86. PubMed ID: 977954
[TBL] [Abstract][Full Text] [Related]
11. Chemotactic activity generated in human serum from the fifth component of complement by hydrogen peroxide.
Shingu M; Nobunaga M
Am J Pathol; 1984 Nov; 117(2):201-6. PubMed ID: 6388344
[TBL] [Abstract][Full Text] [Related]
12. A role for C5 and C5a-ase in the acute neutrophil response to group B streptococcal infections.
Bohnsack JF; Widjaja K; Ghazizadeh S; Rubens CE; Hillyard DR; Parker CJ; Albertine KH; Hill HR
J Infect Dis; 1997 Apr; 175(4):847-55. PubMed ID: 9086140
[TBL] [Abstract][Full Text] [Related]
13. Purification of the proteinase from group B streptococci that inactivates human C5a.
Bohnsack JF; Zhou XN; Williams PA; Cleary PP; Parker CJ; Hill HR
Biochim Biophys Acta; 1991 Aug; 1079(2):222-8. PubMed ID: 1911845
[TBL] [Abstract][Full Text] [Related]
14. The in vivo effect of leukotriene B4 on polymorphonuclear leukocytes and the microcirculation. Comparison with activated complement (C5a des Arg) and enhancement by prostaglandin E2.
Movat HZ; Rettl C; Burrowes CE; Johnston MG
Am J Pathol; 1984 May; 115(2):233-44. PubMed ID: 6326579
[TBL] [Abstract][Full Text] [Related]
15. Chemotactic factor inactivator interaction with Gc-globulin (vitamin D-binding protein). A mechanism of modulating the chemotactic activity of C5a.
Robbins RA; Hamel FG
J Immunol; 1990 Mar; 144(6):2371-6. PubMed ID: 2313096
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of the group A streptococcal C5a inactivator.
Wexler DE; Chenoweth DE; Cleary PP
Proc Natl Acad Sci U S A; 1985 Dec; 82(23):8144-8. PubMed ID: 3906656
[TBL] [Abstract][Full Text] [Related]
17. Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species.
Bohnsack JF; Chang JK; Hill HR
Infect Immun; 1993 Apr; 61(4):1421-6. PubMed ID: 8454345
[TBL] [Abstract][Full Text] [Related]
18. Effect of group B streptococcal type-specific antigen on polymorphonuclear leukocyte function and polymorphonuclear leukocyte-endothelial cell interaction.
McFall TL; Zimmerman GA; Augustine NH; Hill HR
Pediatr Res; 1987 Jun; 21(6):517-23. PubMed ID: 3037472
[TBL] [Abstract][Full Text] [Related]
19. Attachment of human C5a des Arg to its cochemotaxin is required for maximum expression of chemotactic activity.
Perez HD; Chenoweth DE; Goldstein IM
J Clin Invest; 1986 Dec; 78(6):1589-95. PubMed ID: 3782473
[TBL] [Abstract][Full Text] [Related]
20. Chemotactic factor inactivation by stimulated human neutrophils mediated by myeloperoxidase-catalyzed methionine oxidation.
Clark RA; Szot S
J Immunol; 1982 Apr; 128(4):1507-13. PubMed ID: 6278020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
